The Medical Letter on Drugs and Therapeutics
COVID-19 Update: Evusheld Unlikely to Neutralize XBB.1.5 Omicron Variant (online only)
Download PDF:   US English
Med Lett Drugs Ther. 2023 Feb 6;65(1669):e25   doi:10.58347/tml.2023.1669e
 Select a term to see related articles     cilgavimab   COVID-19   Evusheld   tixagevimab 

The FDA has warned that the investigational long-acting monoclonal antibodies tixagevimab and cilgavimab (Evusheld – AstraZeneca) are unlikely to neutralize the XBB.1.5 Omicron variant of SARS-CoV-2.1 Evusheld is available under an Emergency Use Authorization (EUA) for IM pre-exposure prophylaxis of COVID-19 in persons ≥12 years old who weigh ≥40 kg and have either a history of a severe adverse reaction that prevents their vaccination against COVID-19 or moderate or severe immune compromise.2,3

According to the FDA, because tixagevimab and cilgavimab do not neutralize the XBB Omicron variant of SARS-CoV-2, they are unlikely to neutralize the closely related XBB.1.5 variant.1 The CDC has estimated that the XBB.1.5 variant caused 43% of COVID-19 cases in the week ending January 14, 2023, up from 7% of cases 4 weeks earlier.4

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article